In the Literature

Standard pediatric chemotherapy regimens used in the treatment of children and adolescents with high-risk Hodgkin lymphoma are often associated with late effects, including second cancers, infertility, and cardiovascular disease, as well as significantly reduced overall survival (OS). Read More ›

• Daily Aspirin Does Not Lower CRC Risk When Started After Age 70
• Adjuvant Nivolumab Therapy Prolongs Disease-Free Survival in Patients with Esophageal Cancer
• New Data Reveal Mismatched Need and Supply of Oncology Physicians and Pharmacists

Read More ›

Induction chemotherapy leads to remission in many patients with acute myeloid leukemia (AML) aged ≥60 years; however, the disease relapses in most patients, resulting in poor overall survival (OS). Read More ›

• Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
• Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
• Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality

Read More ›

• Selinexor-Dexamethasone Combination Improves Outcomes in Patients with Multiple Myeloma Refractory to 3 Drug Classes
• Five-Year Survival Rates with BRAF-MEK Inhibitors in Metastatic Melanoma with BRAF Mutation

Read More ›

• New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
• Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
• Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL

Read More ›

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. Read More ›

• Venetoclax plus Rituximab Improves Outcomes in Chronic Lymphocytic Leukemia
• Lay Navigation Reduces Medicare Costs, Resource Utilization
• Adding Antiandrogen Therapy Improves Survival in Recurrent Prostate Cancer

Read More ›

• Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
• Mutations Responsible for Relapse Despite PD-1 Therapy Uncovered in Melanoma
• Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma

Read More ›

• Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
• Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
• Enzalutamide Superior to Bicalutamide in Patients with Prostate Cancer

Read More ›